                         SEQUENCE LISTING

<110>  Centre national de la recherche scientifique
       Institut Pasteur de Lille
 
<120>  Procd de ligation native de polypeptides

<130>  30657

<160>  23    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  N(CH2CH2SH)2 group at the C-terminal end

<400>  1

Gly Phe Gly Gln Gly Phe Gly Gly 
1               5               


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  N(CH2CH2SH)2 group at the C-terminal end

<400>  2

Ile Leu Lys Glu Pro Val His Gly Gly 
1               5                   


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  N(CH2CH2SH)2 group at the C-terminal end

<400>  3

Ile Leu Lys Glu Pro Val His Gly Ala 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  N(CH2CH2SH)2 group at the C-terminal end

<400>  4

Ile Leu Lys Glu Pro Val His Gly Val 
1               5                   


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  N(CH2CH2SH)2 group at the C-terminal end

<400>  5

Ile Leu Lys Glu Pro Val His Gly Tyr 
1               5                   


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  NH2 group at the C-terminal end

<400>  6

Cys Ile Leu Lys Glu Pro Val His Gly Val 
1               5                   10  


<210>  7
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  N(CH2CH2SH)2 group at the C-terminal end

<400>  7

Cys His His Leu Glu Pro Gly Gly 
1               5               


<210>  8
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis

<400>  8

Gly Phe Gly Gln Gly Phe Gly Gly 
1               5               


<210>  9
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by ligation


<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  NH2 group at the C-terminal end

<400>  9

Ile Leu Lys Glu Pro Val His Gly Gly Cys Ile Leu Lys Glu Pro Val 
1               5                   10                  15      


His Gly Val 
            


<210>  10
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by ligation


<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  NH2 group at the C-terminal end

<400>  10

Ile Leu Lys Glu Pro Val His Gly Ala Cys Ile Leu Lys Glu Pro Val 
1               5                   10                  15      


His Gly Val 
            


<210>  11
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by ligation


<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  NH2 group at the C-terminal end

<400>  11

Ile Leu Lys Glu Pro Val His Gly Tyr Cys Ile Leu Lys Glu Pro Val 
1               5                   10                  15      


His Gly Val 
            


<210>  12
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by ligation


<220>
<221>  MISC_FEATURE
<222>  (1)..(8)
<223>  Cyclic peptide

<400>  12

Cys His His Leu Glu Pro Gly Gly 
1               5               


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Dithiazepane group at the C-terminal end

<400>  13

Ile Leu Lys Glu Pro Val His Gly Gly 
1               5                   


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Dithiazepane group at the C-terminal end

<400>  14

Ile Leu Lys Glu Pro Val His Gly Ala 
1               5                   


<210>  15
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Dithiazepane group at the C-terminal end

<400>  15

Ile Leu Lys Glu Pro Val His Gly Val 
1               5                   


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Dithiazepane group at the C-terminal end

<400>  16

Ile Leu Lys Glu Pro Val His Gly Tyr 
1               5                   


<210>  17
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Homocysteine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  NH2 group at the C-terminal end

<400>  17

Xaa Ile Leu Lys Glu Pro Val His Gly Val 
1               5                   10  


<210>  18
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Homocysteine

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  NH2 group at the C-terminal end

<400>  18

Ile Leu Lys Glu Pro Val His Gly Gly Xaa Ile Leu Lys Glu Pro Val 
1               5                   10                  15      


His Gly Val 
            


<210>  19
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Protection of the thiol group, -SH is replaced by -SSC(CH3)3

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Dithiazpane group at the C-terminal end

<400>  19

Ile Arg Asn Cys Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val 
1               5                   10                  15      


Ser Ile Thr Lys Ser Gly Ile Lys 
            20                  


<210>  20
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Thiazolidine protection of the thiol group and the alpha amine 
       group

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Dithiazpane group at the C-terminal end

<400>  20

Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His Ser Phe Leu Pro 
1               5                   10                  15      


Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr 
            20                  25              


<210>  21
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (33)..(33)
<223>  NH2 group at the C-terminal end

<400>  21

Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser 
1               5                   10                  15      


Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu 
            20                  25                  30          


Val 
    


<210>  22
<211>  61
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Thiazolidine protection of the thiol group and the alpha amine 
       group

<220>
<221>  MISC_FEATURE
<222>  (61)..(61)
<223>  NH2 group at the C-terminal end

<400>  22

Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His Ser Phe Leu Pro 
1               5                   10                  15      


Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr Cys Arg Asn Pro 
            20                  25                  30          


Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser Asn Pro Glu Val 
        35                  40                  45              


Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu Val 
    50                  55                  60      


<210>  23
<211>  85
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Obtained by synthesis or ligation


<220>
<221>  MISC_FEATURE
<222>  (85)..(85)
<223>  NH2 group at the C-terminal end

<400>  23

Ile Arg Asn Cys Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val 
1               5                   10                  15      


Ser Ile Thr Lys Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile 
            20                  25                  30          


Pro His Glu His Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu 
        35                  40                  45              


Gln Glu Asn Tyr Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp 
    50                  55                  60                  


Cys Phe Thr Ser Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro 
65                  70                  75                  80  


Gln Cys Ser Glu Val 
                85  


